The UK hib vaccine experience

Archives of Disease in Childhood

Volumn 86, Issue 6, 2002, Pages 396-399

  Heath, P T ^a   McVernon, J ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

CLINICAL FEATURE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

CARRIER STATE; CHILD; CHILD, PRESCHOOL; GREAT BRITAIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; INFANT, NEWBORN; NASOPHARYNX; TREATMENT FAILURE; VACCINATION; VACCINES, CONJUGATE;

EID: 0036260158     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.86.6.396     Document Type: Review

References (34)

1. Bericht uber die thatigkeit der deutschen cholera-kommission in aegpytten and ostindien
2. Variation and type specificity in bacterial species of Haemophilus influenzae
3. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91)
4. Invasive Haemophilus influenzae disease: A population-based evaluation of the role of capsular polysaccharide serotype
5. Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the pre-vaccination era (1990-2)
6. Epidemiology of Haemophilus influenzae type b invasive disease in Wales
7. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme
8. Outcomes of bacterial meningitis in children: A meta-analysis
9. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland
10. Haemophilus influenzae type b conjugate vaccines: A review of efficacy data
11. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule
12. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T
13. Hib immunisation catch up programme in North East Thames
14. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom
15. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age
16. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
17. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
18. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster
19. Immunological response to conjugate vaccines in infants: Follow up study
20. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine
21. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b
22. Effect of nationwide vaccination of 3-month-old infants in the Netherlands with conjugate Haemophilus influenzae type b vaccine: High efficacy and lack of herd immunity
23. Infant Hib vaccination and herd immunity
24. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T
25. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines
26. Prevention of Haemophilus influenzae type b colonization by vaccination: Correlation with serum anti-capsular IgG concentration
27. Invasive Haemophilus influenzae disease in adults
28. Haemophilus influenzae type b disease in the Oxford region
29. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants
30. Non-type b Haemophilus influenzae disease: Clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era
31. Reemergence of Invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska
32. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine
33. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates
34. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis